

Supplementary Results. Supplementary Tables

Supplementary Table S1

Current symptoms and areas affected, overall and by physician-judged disease severity at sampling (Analysis 1).

Characteristic	Physician-judged severity (Analysis 1)		
	Overall (N=378)	Mild (N=318)	Moderate to severe (N=60)*
Number of current symptoms, mean±SD	3.6±3.2	3.1±2.8	5.7±4.1
Number of symptoms, n (%)			
Scaling/flaking	246 (65.1)	198 (62.3)	48 (80.0)
Itching	209 (55.3)	162 (50.9)	47 (78.3)
Red inflamed skin	204 (54.0)	160 (50.3)	44 (73.3)
Redness/discolouration	134 (35.4)	108 (34.0)	26 (43.3)
Burning	103 (27.2)	71 (22.3)	32 (53.3)
Cracked skin	88 (23.3)	66 (20.8)	22 (36.7)
Tender/painful skin	67 (17.7)	47 (14.8)	20 (33.3)
Stinging	65 (17.2)	48 (15.1)	17 (28.3)
Tightness	60 (15.9)	42 (13.2)	18 (30.0)
Nail pitting or deformation	36 (9.5)	24 (7.5)	12 (20.0)
Number of current areas affected, mean±SD	1.7±1.9	1.3±1.4	3.7±2.7
Number of areas affected, n (%)			
Knees	107 (28.3)	78 (24.5)	29 (48.3)
Scalp	97 (25.7)	76 (23.9)	21 (35.0)
Elbows	85 (22.5)	58 (18.2)	27 (45.0)
Legs	62 (16.4)	38 (11.9)	24 (40.0)
Back	51 (13.5)	25 (7.9)	26 (43.3)
Chest	43 (11.4)	29 (9.1)	14 (23.3)
Buttocks	33 (8.7)	15 (4.7)	18 (30.0)
Arms	31 (8.2)	15 (4.7)	16 (26.7)
Groin or genitals	30 (7.9)	17 (5.3)	13 (21.7)
Nails	21 (5.6)	14 (4.4)	7 (11.7)

*Only two patients had severe disease at sampling. Only the 10 most common symptoms are areas affected are displayed. N, total number of patients per group; n, number of patients with outcome; SD, standard deviation.

Supplementary Table SII

Table SII: Clinical characteristics of the subset of patients not experiencing a flare at sampling, overall and by physician-judged disease severity at sampling (Analysis 1).

Characteristic	Physician-judged severity (Analysis 1)		
	Total (N=360)	Mild (N=308)	Moderate to severe (N=52)*
BSA %, mean±SD	3.4±4.9	2.6±4.1	7.9±6.2
PASI, mean±SD	4.3±8.9	3.4±8.8	9.1±7.8
Current PGA score, N (%)			
PGA 0–1	227 (63.1)	221 (71.8)	46 (88.5)
PGA 2–4	133 (36.9)	87 (28.2)	46 (88.5)
Number of current symptoms, mean±SD	3.5±3.2	3.1±2.8	5.7±4.3
Type of current symptoms, n (%)			
Scaling/flaking	229 (63.6)	188 (61.0)	41 (78.8)
Itching	192 (53.3)	153 (49.7)	39 (75.0)
Red inflamed skin	190 (52.8)	152 (49.4)	38 (73.1)
Redness/discoloration	125 (34.7)	103 (33.4)	22 (42.3)
Burning	93 (25.8)	66 (21.4)	27 (51.9)
Cracked skin	84 (23.3)	66 (21.4)	18 (34.6)
Tender/painful skin	61 (16.9)	44 (14.3)	17 (32.7)
Stinging	59 (16.4)	46 (14.9)	13 (25.0)
Tightness	55 (15.3)	40 (13.0)	15 (28.8)
Nail pitting or deformation	36 (10.0)	24 (7.8)	12 (23.1)
Number of current areas affected, mean±SD	1.6±1.8	1.3±1.4	3.5±2.6
Current areas affected, n (%)			
Knees	100 (27.8)	76 (24.7)	24 (46.2)
Scalp	89 (24.7)	73 (23.7)	16 (30.8)
Elbows	77 (21.4)	55 (17.9)	22 (42.3)
Legs	54 (15.0)	34 (11.0)	20 (38.5)
Back	46 (12.8)	25 (8.1)	21 (40.4)
Chest	42 (11.7)	29 (9.4)	13 (25.0)
Arms	28 (7.8)	14 (4.5)	14 (26.9)
Groin or genitals	28 (7.8)	16 (5.2)	12 (23.1)
Buttocks	28 (7.8)	14 (4.5)	14 (26.9)
Nails	21 (5.8)	14 (4.5)	7 (13.5)

*Only one patient had severe disease at sampling. Only the 10 most common symptoms areas affected are displayed. BSA, Body Surface Area; N, total number of patients per group; n, number of patients with

outcome; PASI, Psoriasis Area and Severity Index; PGA, Physician's Global Assessment; SD, standard deviation.

Supplementary Table SIII

Table SIII: Clinical characteristics of the subset of patients at sampling by physician type, overall and by physician-judged disease severity at sampling (Analysis 1).

Characteristic	Physician-judged severity (Analysis 1)		
	Overall	Mild	Moderate to severe*
Dermatologists	(N=238)	(N=200, 84.0%)	(N=38, 16.0%)
Current BSA	(N=223)	(N=186)	(N=37)
BSA%, mean±SD	2.8±4.4	1.9±3.3	7.6±5.8
BSA >10, n (%)	13 (5.8)	3 (1.6)	10 (27.0)
Current PGA score, n (%)			
PGA 0–1	161 (67.6)	156 (78.0)	5 (13.2)
PGA 2–4	77 (32.4)	44 (22.0)	33 (86.8)
Current PASI score	(N=206)	(N=174)	(N=32)
PASI, mean±SD	2.1±3.1	1.3±1.7	6.6±4.8
PASI >10, n (%)	6 (2.9)	0 (0.0)	6 (18.8)
Paediatricians	(N=34)	(N=27, 79.4%)	(N=7, 20.6%)
Current BSA			
BSA%, mean±SD	6.3±5.0	5.2±3.0	10.4±8.7
BSA >10, n (%)	2 (5.9)	1 (3.7)	1 (14.3)
Current PGA score, n (%)			
PGA 1	16 (47.1)	16 (59.3)	0 (0.0)
PGA 2–3	18 (52.9)	11 (40.7)	7 (100.0)
Current PASI score	(N=27)	(N=21)	(N=6)
PASI, mean±SD	22.3±18.3	22.3±20.6	22.5±7.6
PASI >10, n (%)	22 (81.5)	17 (81.0)	5 (83.3)
GP/PCPs	(N=88)	(N=81, 92.0%)	(N=7, 8.0%)
Current BSA	(N=65)	(N=60)	(N=5)
BSA%, mean±SD	3.9±5.9	3.6±5.9	6.4±5.9
BSA >10, n (%)	5 (7.7)	4 (6.7)	1 (20.0)
Current PGA score, n (%)			
0–1	50 (56.8)	49 (60.5)	1 (14.3)
2–4	38 (43.2)	32 (39.5)	6 (85.7)
Current PASI score	(N=44)	(N=39)	(N=5)
PASI, mean±SD	3.2±5.3	2.4±4.3	9.0±8.5
PASI >10, n (%)	4 (9.1)	2 (5.1)	2 (40.0)

*Only one patient had severe disease at sampling; this patient was managed by a dermatologist. Where the full number of patients is not available, number of patients per group is indicated within the table (N). BSA, Body Surface Area; GP, general practitioner; N, total number of patients per group; n, number of patients with outcome; PASI, Psoriasis Area and Severity Index; PCP, primary care practitioner; PGA, Physician's Global Assessment; SD, standard deviation.